Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 26 analysts with 12-month price forecasts for Regeneron Pharmaceuticals stock have an average target of 996, with a low estimate of 165 and a high estimate of 1,300. The average target predicts an increase of 42.22% from the current stock price of 700.33.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$165	$996	$1,070	$1,300
Change	-76.44%	+42.22%	+52.79%	+85.63%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock from 26 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '24	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25
Strong Buy	8	8	8	6	6	6
Buy	11	11	12	12	12	13
Hold	5	4	4	5	6	6
Sell	1	1	0	1	1	1
Strong Sell	0	0	0	0	0	0
Total	25	24	24	24	25	26

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brian Skorney Baird	Baird	Hold Maintains $940 → $759	Hold	Maintains	$940 → $759	+8.38%	Feb 5, 2025
David Risinger Leerink Partners	Leerink Partners	Hold → Buy Upgrades $762 → $834	Hold → Buy	Upgrades	$762 → $834	+19.09%	Feb 5, 2025
Geoff Meacham Citigroup	Citigroup	Hold Maintains $795 → $750	Hold	Maintains	$795 → $750	+7.09%	Jan 28, 2025
Christopher Raymond Piper Sandler	Piper Sandler	Buy Maintains $1,195 → $1,013	Buy	Maintains	$1,195 → $1,013	+44.65%	Jan 27, 2025
Trung Huynh UBS	UBS	Strong Buy → Hold Downgrades $1,130 → $738	Strong Buy → Hold	Downgrades	$1,130 → $738	+5.38%	Jan 16, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

14.87B

Increased by 4.68%

from 14.20B

Revenue Next Year

15.69B

Increased by 5.51%

from 14.87B

EPS This Year

43.45

Increased by 13.32%

from 38.34

EPS Next Year

47.12

Increased by 8.45%

from 43.45

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	8.50B	16.07B	12.17B	13.12B	14.20B	14.87B	15.69B	17.22B
Revenue Growth	29.58%	89.14%	-24.26%	7.76%	8.27%	4.68%	5.51%	9.76%
EPS	30.52	71.97	38.22	34.77	38.34	43.45	47.12	55.88
EPS Growth	65.33%	135.81%	-46.89%	-9.03%	10.27%	13.32%	8.45%	18.60%
Forward PE	-	-	-	-	-	16.12	14.86	12.53
No. Analysts	-	-	-	-	-	30	26	21

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	16.3B	17.2B	19.6B
Avg	14.9B	15.7B	17.2B
Low	13.5B	13.7B	14.5B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	14.6%	15.4%	24.9%
Avg	4.7%	5.5%	9.8%
Low	-5.2%	-7.7%	-7.8%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	52.35	58.18	70.91
Avg	43.45	47.12	55.88
Low	34.73	35.46	37.92

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	36.5%	33.9%	50.5%
Avg	13.3%	8.5%	18.6%
Low	-9.4%	-18.4%	-19.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.